These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 23697247)

  • 1. Quality of life in patients with blepharospasm.
    Biuk D; Karin AA; Matić S; Barać J; Benasić T; Stiglmayer N
    Coll Antropol; 2013 Mar; 37(1):29-33. PubMed ID: 23697247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
    Streitová H; Bareš M
    Acta Neurol Belg; 2014 Dec; 114(4):285-91. PubMed ID: 24604684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm.
    Tang M; Li W; Ji F; Li X; Zhang Y; Liu P
    Psychol Health Med; 2019 Jun; 24(5):513-518. PubMed ID: 30463432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact on quality of life of botulinum toxin treatments for essential blepharospasm.
    MacAndie K; Kemp E
    Orbit; 2004 Dec; 23(4):207-10. PubMed ID: 15590520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
    Kongsengdao S; Kritalukkul S
    J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm.
    Ochudlo S; Bryniarski P; Opala G
    Parkinsonism Relat Disord; 2007 Dec; 13(8):505-8. PubMed ID: 17543569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in patients with blepharospasm.
    Tucha O; Naumann M; Berg D; Alders GL; Lange KW
    Acta Neurol Scand; 2001 Jan; 103(1):49-52. PubMed ID: 11153888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographic and clinical features of patients with blepharospasm in southern Taiwan: a university hospital-based study.
    Hwang WJ
    Acta Neurol Taiwan; 2012 Sep; 21(3):108-14. PubMed ID: 23196730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression.
    Müller J; Kemmler G; Wissel J; Schneider A; Voller B; Grossmann J; Diez J; Homann N; Wenning GK; Schnider P; Poewe W;
    J Neurol; 2002 Jul; 249(7):842-6. PubMed ID: 12140667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales.
    Lee RM; Chowdhury HR; Hyer JN; Smith HB; Jones CA
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):196-7. PubMed ID: 23446304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J; Comella C; Hanschmann A; Grafe S
    Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in blepharospasm or hemifacial spasm.
    Reimer J; Gilg K; Karow A; Esser J; Franke GH
    Acta Neurol Scand; 2005 Jan; 111(1):64-70. PubMed ID: 15595940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translation, adaptation, and cross-cultural validation of the CDQ-24 scale in patients with primary blepharospasm under botulinum toxin treatment, pilot test.
    Mejia-Vergara AJ; Méndez Cardona L; Flórez Rocha DA; Rozo N; Rincón López JV
    Arch Soc Esp Oftalmol (Engl Ed); 2024 Aug; 99(8):317-322. PubMed ID: 38878820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supramaximal doses of botulinum toxin for refractory blepharospasm.
    Levy RL; Berman D; Parikh M; Miller NR
    Ophthalmology; 2006 Sep; 113(9):1665-8. PubMed ID: 16828511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
    Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
    J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blepharospasm with non-satisfactory response to treatment: our experience with IncobotulinumtoxinA.
    Ricciardi L; Ialongo T; Guidubaldi A; Di Giacopo R; Bentivoglio AR
    Parkinsonism Relat Disord; 2014 Jun; 20(6):665-7. PubMed ID: 24685658
    [No Abstract]   [Full Text] [Related]  

  • 20. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
    Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
    J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.